Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 9
2003 6
2004 7
2005 6
2006 8
2007 10
2008 7
2009 9
2010 14
2011 9
2012 14
2013 8
2014 14
2015 14
2016 16
2017 22
2018 15
2019 17
2020 26
2021 40
2022 30
2023 19
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

292 results

Results by year

Filters applied: . Clear all
Page 1
Multicenter, randomized, double-blind, placebo-controlled phase 3 study of mogamulizumab with open-label extension study in a minimum number of patients with human T-cell leukemia virus type-1-associated myelopathy.
Sato T, Nagai M, Watanabe O, Misu T, Takenouchi N, Ohkubo R, Ishihara S, Tsuboi Y, Katsuno M, Nakagawa M, Matsushita T, Aso Y, Matsuura E, Tokashiki T, Mukaino A, Adachi H, Nakanishi K, Yamaguchi Y, Yamaguchi S, Yamano Y. Sato T, et al. Among authors: tsuboi y. J Neurol. 2024 Mar 2. doi: 10.1007/s00415-024-12239-x. Online ahead of print. J Neurol. 2024. PMID: 38430272
Validation study of the Japanese version of the King's Parkinson's Disease Pain Scale and the King's Parkinson's Disease Pain Questionnaire.
Kurihara K, Fujioka S, Mizutani Y, Watanabe H, Iwaoka K, Maeda T, Seki M, Tezuka T, Nakahara J, Konno T, Ishiguro T, Onodera O, Asano Y, Takahashi K, Rizos A, Chaudhuri KR, Tsuboi Y. Kurihara K, et al. Among authors: tsuboi y. Parkinsonism Relat Disord. 2024 Mar;120:106012. doi: 10.1016/j.parkreldis.2024.106012. Epub 2024 Jan 28. Parkinsonism Relat Disord. 2024. PMID: 38290410 Free article.
Neurostimulation for Advanced Parkinson Disease and Quality of Life at 5 Years: A Nonrandomized Controlled Trial.
Jost ST, Aloui S, Evans J, Ashkan K, Sauerbier A, Rizos A, Petry-Schmelzer JN, Gronostay A, Fink GR, Visser-Vandewalle V, Antonini A, Silverdale M, Timmermann L, Martinez-Martin P, Chaudhuri KR, Dafsari HS; International Parkinson and Movement Disorders Society Non-Motor Parkinson’s Disease Study Group and EUROPAR. Jost ST, et al. JAMA Netw Open. 2024 Jan 2;7(1):e2352177. doi: 10.1001/jamanetworkopen.2023.52177. JAMA Netw Open. 2024. PMID: 38236600 Free PMC article. Clinical Trial.
Impact of Istradefylline on Levodopa Dose Escalation in Parkinson's Disease: ISTRA ADJUST PD Study, a Multicenter, Open-Label, Randomized, Parallel-Group Controlled Study.
Hatano T, Sengoku R, Nagayama H, Yanagisawa N, Yoritaka A, Suzuki K, Nishikawa N, Mukai Y, Nomura K, Yoshida N, Seki M, Matsukawa MK, Terashi H, Kimura K, Tashiro J, Hirano S, Murakami H, Joki H, Uchiyama T, Shimura H, Ogaki K, Fukae J, Tsuboi Y, Takahashi K, Yamamoto T, Kaida K, Ihara R, Kanemaru K, Kano O. Hatano T, et al. Among authors: tsuboi y. Neurol Ther. 2024 Apr;13(2):323-338. doi: 10.1007/s40120-023-00574-6. Epub 2024 Jan 16. Neurol Ther. 2024. PMID: 38227133 Free PMC article.
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group. Bateman RJ, et al. N Engl J Med. 2023 Nov 16;389(20):1862-1876. doi: 10.1056/NEJMoa2304430. N Engl J Med. 2023. PMID: 37966285 Clinical Trial.
292 results